Given the pleiotropic effects of IGF‐1 in the brain and periphery, many of which are beneficial, we propose that modulating this axis to promote healthspan in humans should be viewed as a ‘balance’ between its central and peripheral actions, to maximize its benefits, particularly in the CNS, while minimizing cancer risk in the periphery. The gene discussed is IGF1; the disease is cancer.